Brokers Offer Predictions for ZNTL Q3 Earnings

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) - Investment analysts at Leerink Partnrs issued their Q3 2025 earnings estimates for shares of Zentalis Pharmaceuticals in a research note issued on Wednesday, February 5th. Leerink Partnrs analyst A. Berens anticipates that the company will post earnings of ($0.41) per share for the quarter. The consensus estimate for Zentalis Pharmaceuticals' current full-year earnings is ($2.42) per share. Leerink Partnrs also issued estimates for Zentalis Pharmaceuticals' FY2025 earnings at ($2.00) EPS and FY2026 earnings at ($1.81) EPS.

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.56) EPS for the quarter, beating the consensus estimate of ($0.92) by $0.36.

ZNTL has been the topic of a number of other reports. HC Wainwright reduced their price objective on Zentalis Pharmaceuticals from $20.00 to $10.00 and set a "buy" rating on the stock in a research note on Wednesday, January 29th. UBS Group decreased their price objective on shares of Zentalis Pharmaceuticals from $5.00 to $2.20 and set a "neutral" rating on the stock in a research report on Tuesday, January 28th. Wedbush reiterated a "neutral" rating and set a $4.00 target price on shares of Zentalis Pharmaceuticals in a report on Friday, January 24th. Wells Fargo & Company cut their target price on Zentalis Pharmaceuticals from $8.00 to $6.00 and set an "equal weight" rating on the stock in a research note on Thursday, January 30th. Finally, Guggenheim lowered their price target on Zentalis Pharmaceuticals from $12.00 to $8.00 and set a "buy" rating for the company in a research report on Friday, November 15th. Five research analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus price target of $8.24.

Zentalis Pharmaceuticals Stock Up 12.5 %

Shares of Zentalis Pharmaceuticals stock traded up $0.27 during trading on Monday, reaching $2.43. The company's stock had a trading volume of 1,568,832 shares, compared to its average volume of 2,689,611. The company has a market cap of $173.16 million, a price-to-earnings ratio of -0.98 and a beta of 1.81. The firm's 50-day moving average is $2.67 and its two-hundred day moving average is $3.14. Zentalis Pharmaceuticals has a 52-week low of $1.61 and a 52-week high of $18.07.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in ZNTL. China Universal Asset Management Co. Ltd. raised its holdings in Zentalis Pharmaceuticals by 63.9% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,676 shares of the company's stock worth $50,000 after acquiring an additional 5,333 shares during the last quarter. Wells Fargo & Company MN increased its holdings in shares of Zentalis Pharmaceuticals by 26.8% in the 4th quarter. Wells Fargo & Company MN now owns 34,609 shares of the company's stock worth $105,000 after purchasing an additional 7,305 shares in the last quarter. Carson Advisory Inc. increased its holdings in shares of Zentalis Pharmaceuticals by 55.8% in the 3rd quarter. Carson Advisory Inc. now owns 24,570 shares of the company's stock worth $90,000 after purchasing an additional 8,800 shares in the last quarter. Erste Asset Management GmbH purchased a new position in shares of Zentalis Pharmaceuticals in the third quarter worth $37,000. Finally, Paloma Partners Management Co bought a new position in shares of Zentalis Pharmaceuticals during the third quarter valued at $37,000.

Insider Transactions at Zentalis Pharmaceuticals

In other news, Director Jan Skvarka purchased 60,000 shares of the company's stock in a transaction that occurred on Friday, January 31st. The shares were bought at an average price of $1.72 per share, for a total transaction of $103,200.00. Following the purchase, the director now directly owns 149,551 shares in the company, valued at approximately $257,227.72. This trade represents a 67.00 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Ingmar Bruns acquired 20,000 shares of Zentalis Pharmaceuticals stock in a transaction on Thursday, February 6th. The shares were purchased at an average price of $2.28 per share, with a total value of $45,600.00. Following the completion of the purchase, the insider now owns 36,629 shares in the company, valued at $83,514.12. This represents a 120.27 % increase in their position. The disclosure for this purchase can be found here. Insiders own 3.60% of the company's stock.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.